Back
PubMed

Lynch syndrome

Ryan NAJ, Gallon R, McVeigh T, et al. — Lancet 2026 · November 2026
Relevance score
5/10
Disease / domain
Lynch syndrome
Source
PubMed
PMID 43020098

Gene / mechanism

Germline pathogenic variants in DNA mismatch repair (MMR) genes

Summary

Lynch syndrome is the most common inherited cancer predisposition syndrome, affecting approximately one in 350-450 individuals, yet most carriers remain undiagnosed. Caused by germline pathogenic variants in MMR genes, it confers markedly elevated and heterogeneous risks of colorectal, endometrial and multiple extracolonic cancers. This review covers the whole continuum of care, starting with universal tumour testing for MMR deficiency, which has transformed case identification and enabled targeted germline testing and cascade screening, but whose implementation remains inconsistent, with attrition along diagnostic pathways. It details prevention through colonoscopic surveillance, aspirin chemoprevention and risk-reducing surgery, to be applied in a gene-specific and individualised way. Finally, it addresses immune checkpoint inhibitors in MMR-deficient tumours and emerging vaccine strategies for cancer interception.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

A reference review for teaching and clinic, focusing on the persistent weak point: most carriers remain unidentified despite universal tumour testing. The emphasis on gene-specific prevention is welcome, but the review brings no new data. Emerging vaccine strategies for cancer interception are the lead to watch.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 1/3Novelty 1/2Sample 0/1Publication 1/1

Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 5/10

Keywords

Lynch syndromeMMR genescascade screeningaspirinimmunotherapy
Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime